Mr. Barthel L. Barthel is an experienced executive leader in the healthcare and medical device space with the proven ability to straddle the worlds of large corporations and early-stage businesses. Has relevant P&L and senior leadership experience as a Managing Director for Henry Schein’s Orthopedic Surgical Instrumentation business, as an Area Vice President for the Southeast Division for Medtronic GIH in Atlanta, GA and as Vice President, SmartPill for Given Imaging in Duluth, GA. Previously as President and CEO, led The SmartPill Corp., a GI medical device start-up in Buffalo, NY from a patent for an ingestible motility capsule through product development, fund raising, clinical trials, FDA approvals, manufacturing, reimbursement, commercialization and eventual sale of the business.
Mr. Barthel has coordinated and executed multiple capital fundraising efforts, driving significant revenue growth and has the ability to establish commercial viability across multiple disciplines, strategic partners and sales channels. David’s focus has been on building businesses through strategic partnerships, global market and channel development, talent and cross functional team development and the creation of economic and clinical value propositions that drive sustainable growth.
Mr. Barthel earned a Bachelor of Arts Degree from St. Norbert College in Depere, Wi and an MBA from Lake Forest Graduate School of Management in Lake Forest, Il.
Dr. Pachuk has more than 25 years of research and development leadership experience in the pharmaceutical and biotech sectors, with expertise in drug, device, and vaccine development. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. Dr. Pachuk is currently a Scientific Advisory Board member for Ocugen, Inc. where she advises on the development of a COVID-19 vaccine and is currently an invited expert curator for the American Society of Microbiology’s COVID-19 research registry. She is also an adjunct faculty member at both Florida Atlantic University and Baruch Blumberg Institute.
Following a post-doctoral fellowship at SmithKline Beecham, she joined Apollon, Inc. to develop programs in oligonucleotide-based therapeutics, and subsequently DNA-based vaccines for both viral and oncology indications. Following the acquisition of Apollon, Inc. by Wyeth-Ayerst Research in 1998 she continued to direct several vaccine programs, which resulted in several plasmid-based vaccine products being advanced into clinical trials. During this time, Dr. Pachuk worked with FDA’S CBER division in the drafting of a “Points to Consider” document regarding considerations for administration of plasmid DNA compounds in humans. In 2001, she co-founded Nucleonics, a biotech focused on the development of RNAi-based therapeutics, one of which was advanced into clinical studies in Chronic Hepatitis B patients. Until April 2008, she was VP of Preclinical Research. Dr. Pachuk then went on to lead biology and preclinical development efforts for Pfizer’s oligonucleotide therapeutic programs (ASO and siRNA) in the areas of oncology and metabolic disease and was a member of the Executive Leadership Team. Dr. Pachuk also has significant experience in nucleic-acid delivery and has led nucleic acid-delivery and formulation development programs for ASO, plasmid-based therapeutics, and siRNA at Apollon/Wyeth Vaccines, Nucleonics and Pfizer. Dr. Pachuk also was responsible for obtaining more than $1.8 million in government and private grants.
Dr. Pachuk received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. Dr. Pachuk also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in medical devices and pharmaceuticals.
Mr. Barthel L. Barthel is an experienced executive leader in the healthcare and medical device space with the proven ability to straddle the worlds of large corporations and early-stage businesses. Has relevant P&L and senior leadership experience as a Managing Director for Henry Schein’s Orthopedic Surgical Instrumentation business, as an Area Vice President for the Southeast Division for Medtronic GIH in Atlanta, GA and as Vice President, SmartPill for Given Imaging in Duluth, GA. Previously as President and CEO, led The SmartPill Corp., a GI medical device start-up in Buffalo, NY from a patent for an ingestible motility capsule through product development, fund raising, clinical trials, FDA approvals, manufacturing, reimbursement, commercialization and eventual sale of the business.
Mr. Barthel has coordinated and executed multiple capital fundraising efforts, driving significant revenue growth and has the ability to establish commercial viability across multiple disciplines, strategic partners and sales channels. David’s focus has been on building businesses through strategic partnerships, global market and channel development, talent and cross functional team development and the creation of economic and clinical value propositions that drive sustainable growth.
Mr. Barthel earned a Bachelor of Arts Degree from St. Norbert College in Depere, Wi and an MBA from Lake Forest Graduate School of Management in Lake Forest, Il.
Dr. Pachuk has more than 25 years of research and development leadership experience in the pharmaceutical and biotech sectors, with expertise in drug, device, and vaccine development. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. Dr. Pachuk is currently a Scientific Advisory Board member for Ocugen, Inc. where she advises on the development of a COVID-19 vaccine and is currently an invited expert curator for the American Society of Microbiology’s COVID-19 research registry. She is also an adjunct faculty member at both Florida Atlantic University and Baruch Blumberg Institute.
Following a post-doctoral fellowship at SmithKline Beecham, she joined Apollon, Inc. to develop programs in oligonucleotide-based therapeutics, and subsequently DNA-based vaccines for both viral and oncology indications. Following the acquisition of Apollon, Inc. by Wyeth-Ayerst Research in 1998 she continued to direct several vaccine programs, which resulted in several plasmid-based vaccine products being advanced into clinical trials. During this time, Dr. Pachuk worked with FDA’S CBER division in the drafting of a “Points to Consider” document regarding considerations for administration of plasmid DNA compounds in humans. In 2001, she co-founded Nucleonics, a biotech focused on the development of RNAi-based therapeutics, one of which was advanced into clinical studies in Chronic Hepatitis B patients. Until April 2008, she was VP of Preclinical Research. Dr. Pachuk then went on to lead biology and preclinical development efforts for Pfizer’s oligonucleotide therapeutic programs (ASO and siRNA) in the areas of oncology and metabolic disease and was a member of the Executive Leadership Team. Dr. Pachuk also has significant experience in nucleic-acid delivery and has led nucleic acid-delivery and formulation development programs for ASO, plasmid-based therapeutics, and siRNA at Apollon/Wyeth Vaccines, Nucleonics and Pfizer. Dr. Pachuk also was responsible for obtaining more than $1.8 million in government and private grants.
Dr. Pachuk received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. Dr. Pachuk also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in medical devices and pharmaceuticals.
Mr. Kovalyov was most recently COO of My Health Logic Inc., the Company acquired by Marizyme in December 2021. Before that, he was Vice President Finance at Phivida Holdings Inc (VIDA: CSE), a publicly traded company that has raised over $19 million since its IPO in December 2017 before its merger with larger (CHOOM:CSE). Mr. Kovalyov is also Founder and President of GVK Group Chartered Accountant. He has Over $20 million in capital raising and capital management experience and as the Founder of GVK Group, sold to MCA Chartered Accountants. He has spent 11 years as an experienced financial controller, working on public companies audits and financial statements to GAAP and IFRS.
Mr.Kovalyov received his Chartered Accountant designation through the Institute of Chartered Accountants of British Columbia and Bachelor of Business Administration, Diploma in Accounting – Kwantlen University
Mr. Ross brings experience in both public and private capitals markets, enhanced by a strong background in equity research and valuation. Mr. Ross was recently CFO at My Health Logic, the Company which was acquired by Marizyme in December 2021. Mr. Ross was also CFO at DC Acquisition Corp., a Capital Pool Company listed on the TSX.V that raised $3 million and successfully completed an RTO of Kiaro Holdings (TSXV:KO). Mr. Ross has assisted in the management over $500 million aat investment management firms and family offices. Mr. Ross is also an independent director of Codebase Ventures Inc. (CSE:CODE) which seeks early-stage investments in emerging technology sectors.
Mr. Ross received his Bachelor of Management and Organizational Studies degree from University of Western Ontario, with specialization in Accounting. Mr. Ross is a CFA Charterholder.
Mr. Kovalyov was most recently COO of My Health Logic Inc., the Company acquired by Marizyme in December 2021. Before that, he was Vice President Finance at Phivida Holdings Inc (VIDA: CSE), a publicly traded company that has raised over $19 million since its IPO in December 2017 before its merger with larger (CHOOM:CSE). Mr. Kovalyov is also Founder and President of GVK Group Chartered Accountant. He has Over $20 million in capital raising and capital management experience and as the Founder of GVK Group, sold to MCA Chartered Accountants. He has spent 11 years as an experienced financial controller, working on public companies audits and financial statements to GAAP and IFRS.
Mr.Kovalyov received his Chartered Accountant designation through the Institute of Chartered Accountants of British Columbia and Bachelor of Business Administration, Diploma in Accounting – Kwantlen University
Dr. Rigatto is a kidney disease specialist and Associate Professor of Medicine at the University of Manitoba, as well as the Academic Director of the Chronic Disease Innovation Centre. As a clinician, Dr. Rigatto deeply engaged in the care of patients with CKD or on dialysis, with a focus on home treatments of kidney disease. As a researcher, Dr. Rigatto has deep expertise in biomarkers, risk prediction, and virtual care methods. His research program is focused on developing and implementing technologies to help patients self-manage complex health conditions at home.
He has developed point-of-care test for early detection and risk prediction in CKD, as well as tablet based tools to monitor patient health status at home (telemonitoring). He has published over 180 peer-reviewed articles, and has presented at numerous national and international meetings. Dr. Rigatto is co-founder of the lab-on-chip technology asset that was part of the My Health Logic acquisition.
In addition to his clinical and academic work, he currently serves as President-Elect of the Canadian Society of Nephrology, Associate Editor for the Canadian Journal of Kidney Health and Disease, and as investigator and subcommittee co-chair of the Can-SOLVE-CKD network of patient oriented research programs. He received his medical training at the University of Manitoba, including a BSc. in Medicine and at Memorial University in Newfoundland where he received his MSc. in Medicine.
Mr. Kovalyov was most recently COO of My Health Logic Inc., the Company acquired by Marizyme in December 2021. Before that, he was Vice President Finance at Phivida Holdings Inc (VIDA: CSE), a publicly traded company that has raised over $19 million since its IPO in December 2017 before its merger with larger (CHOOM:CSE). Mr. Kovalyov is also Founder and President of GVK Group Chartered Accountant. He has Over $20 million in capital raising and capital management experience and as the Founder of GVK Group, sold to MCA Chartered Accountants. He has spent 11 years as an experienced financial controller, working on public companies audits and financial statements to GAAP and IFRS.
Mr.Kovalyov received his Chartered Accountant designation through the Institute of Chartered Accountants of British Columbia and Bachelor of Business Administration, Diploma in Accounting – Kwantlen University
Mr. Ross brings experience in both public and private capitals markets, enhanced by a strong background in equity research and valuation. Mr. Ross was recently CFO at My Health Logic, the Company which was acquired by Marizyme in December 2021. Mr. Ross was also CFO at DC Acquisition Corp., a Capital Pool Company listed on the TSX.V that raised $3 million and successfully completed an RTO of Kiaro Holdings (TSXV:KO). Mr. Ross has assisted in the management over $500 million aat investment management firms and family offices. Mr. Ross is also an independent director of Codebase Ventures Inc. (CSE:CODE) which seeks early-stage investments in emerging technology sectors.
Mr. Ross received his Bachelor of Management and Organizational Studies degree from University of Western Ontario, with specialization in Accounting. Mr. Ross is a CFA Charterholder.
Mr. Dhaduk was named Director of Business Development at Marizyme in 2021. He previous roles include serving as President of Global Pharma Analytics for 3 years, Vice President of Business Affairs for Somahlution for 5 years where he helped lead efforts for commercializing and marketing after pursuing his BA in Finance. His responsibilities include medical device marketing, project management, customer/distributor relationship management, and business development.
Mr. Dhaduk was named Director of Business Development at Marizyme in 2021. He previous roles include serving as President of Global Pharma Analytics for 3 years, Vice President of Business Affairs for Somahlution for 5 years where he helped lead efforts for commercializing and marketing after pursuing his BA in Finance. His responsibilities include medical device marketing, project management, customer/distributor relationship management, and business development.